| Literature DB >> 28386631 |
Victor U Irorere1, Lakshmi Tripathi1, Roger Marchant1, Stephen McClean1, Ibrahim M Banat2.
Abstract
High production cost and potential pathogenicity of Pseudomonas aeruginosa, commonly used for rhamnolipid synthesis, have led to extensive research for safer producing strains and cost-effective production methods. This has resulted in numerous research publications claiming new non-pathogenic producing strains and novel production techniques many of which are unfortunately without proper characterisation of product and/or producing strain/s. Genes responsible for rhamnolipid production have only been confirmed in P. aeruginosa, Burkholderia thailandensis and Burkholderia pseudomallei. Comparing yields in different publications is also generally unreliable especially when different methodologies were used for rhamnolipid quantification. After reviewing the literature in this area, we strongly feel that numerous research outputs have insufficient evidence to support claims of rhamnolipid-producing strains and/or yields. We therefore recommend that standards should be set for reporting new rhamnolipid-producing strains and production yields. These should include (1) molecular and bioinformatic tools to fully characterise new microbial isolates and confirm the presence of the rhamnolipid rhl genes for all bacterial strains, (2) using gravimetric methods to quantify crude yields and (3) use of a calibrated method (high-performance liquid chromatography or ultra-performance liquid chromatography) for absolute quantitative yield determination.Entities:
Keywords: Biosurfactant quantification; Biosurfactants; Microbial identification; Rhamnolipid; Rhamnolipid genes
Mesh:
Substances:
Year: 2017 PMID: 28386631 PMCID: PMC5403872 DOI: 10.1007/s00253-017-8262-0
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Potential applications of rhamnolipid in different industries
| Industry | Application | Reference |
|---|---|---|
| Biomedical | Antimicrobial and/or antiviral agents | Cortés-Sánchez et al. ( |
| Treatment of autoimmune disease | Piljac and Piljac ( | |
| Wound healing, treatment of gum disease and periodontal regeneration | Stipcevic et al. ( | |
| Treatment of ulcer | Piljac et al. ( | |
| Environmental | Biodegradation of organic compounds | Maier and Soberón-Chávez ( |
| Adsorption and composting of heavy metals | Fu et al. ( | |
| Environmental disinfection and cleaning | DeSanto ( | |
| Cosmetics and pharmaceutical industries | Treatment of radiation burns | DeSanto ( |
| Treatment of wrinkles and signs of ageing | Piljac and Piljac ( | |
| Used in antidandruff products, nail care products and toothpaste | Lourith and Kanlayavattanakul ( | |
| Other industries | It is used in the food industry as a multipurpose ingredient as well as serving as a source of L-rhamnose and conditioning of food surfaces | Rikalović et al. ( |
| In the agricultural industries, it is used for remediating agricultural soils, improving microbial plant interaction, improving plant nutrient absorption, as biopesticides and as antimicrobial agents for farm animals | Rikalović et al. ( | |
| It is also used in nanotechnology for the formulation of microemulsion and synthesis of nanoparticles as well as in the formulations of drug delivery systems | Rikalović et al. ( |
Microorganisms with claims of rhamnolipid production, including method of microbial identification and rhamnolipid characterisation
| Reference | Organism | Organism identification method(s) | Biosurfactant type | Characterisation method | Biosurfactant/rhamnolipid yield (mg/L) | Yield determination method(s) |
|
|---|---|---|---|---|---|---|---|
| El-Amine et al. ( |
| Phenotypic identification, API 20E strip, using selective media and fluorescence properties | Rhamnolipid | NA | 105.756 ± 2.076 | Rhamnose measurement by UV spectroscopy | NA |
| Additional information/remarks: No rhamnolipid extraction recorded with supernatant used to test emulsification activity, oil displacement and drop collapse. Insufficient evidence to support rhamnolipid production, yield and isolate characterisation. | |||||||
| Nalini and Parthasarathi ( |
| 16S rRNA sequencing | Rhamnolipid | GC-MS, FTIR, thin-layer chromatography | Not indicated | Emulsification index |
|
| Additional information/remarks: Rhamnolipid was extracted, but its weight was not recorded. Rha-Rha-C16-C10 and Rha-Rha-C14-C10 were reported as the major rhamnolipid congeners. Requires further molecular evidence to identify | |||||||
| Nordin et al. ( |
| Phenotypic and morphological techniques, Biolog GEN III | No specific Bs identified | NA | 432 | Gravimetric | NA |
| Additional information/remarks: Oil spreading, drop collapse test and emulsification index were used as evidence of biosurfactant production. Requires further evidence to support claim including the presence of | |||||||
| Gunther et al. ( |
| Referenced as identified previously by Stanier et al. ( | Rhamnolipid | TLC and HPLC/MS | >355 | Gravimetric | NA |
| Additional information/remarks: Only mono-rhamnolipid congeners identified: Rha-C10-C10, Rha-C12-C10, Rha-C12:1-C10, Rha-C12-C12, Rha-C12:1-C12, Rha-C14-C10, Rha-C14:1-C10 and Rha-C10-C8. Requires 16S rDNA characterisation of producing organism, also requires molecular evidence to support claims of rhamnolipid production. | |||||||
| Vasileva-Tonkova et al. ( |
| Morphological and biochemical identification following the Bergey’s Manual of Determinative Bacteriology. | Glycolipid ‘assumed to be rhamnolipid’ | Haemolysis, growth inhibition of | 1400 ± 220 | Orcinol assay on extracted product | NA |
| Additional information/remarks: It decreased the surface tension of water to 35 mN/m with critical micelle concentration of 20 mg/L. Requires 16S rDNA sequencing for isolate identification, need to show at least one rhamnolipid congener and need to show molecular evidence (presence of | |||||||
| Tuleva Borjana et al. ( |
| Morphological and biochemical characterisation using the Bergey’s manual. | Rhamnolipid | Haemolysis, growth inhibition of | 1200 | Orcinol assay on extracted product | NA |
| Additional information/remark: The surface tension of the media was reported to be reduced to 29 mN/m with emulsifying activity of kerosene reaching up to 69%. Requires 16S rDNA sequencing for isolate identification, need to show at least one rhamnolipid congener and need to show molecular evidence (presence of | |||||||
| Priji et al. ( |
| 16S rRNA sequencing | Rhamnolipid type assumed to be rhamnolipid | FTIR, TLC, orcinol | 2070 | Gravimetric | NA |
| Additional information/remark: Minimum surface tension observed 35–40 mN/m. No determination of congener composition or definitive identification of biosurfactant. Need to show at least one rhamnolipid congener and need to show molecular evidence (presence of | |||||||
| Rooney et al. ( |
| 16S rRNA sequencing | Rhamnolipid | Matrix-assisted laser desorption/ionisation time-of-flight MS (MALDI-TOF/MS) | 1900 to 2400 | Gravimetric | NA |
| Additional information/remark: The strains were isolated alongside strains of | |||||||
| Dubeau et al. ( |
| 16s rDNA, referencing (Brett et al. | Rhamnolipid | HPLC/MS/MS | ∼260 | LC/MS | Yes |
| Additional information/remark: The | |||||||
| Christova et al. ( |
| Physiological and biochemical tests following the Bergey’s manual | Rhamnolipid | TLC and infrared spectrometer | Up to 920 | Orcinol assay | NA |
| Additional information/remarks: The IR spectra were compared to that obtained from commercially available rhamnolipids for conclusive evidence on rhamnolipid production. Need to show at least one rhamnolipid congener and need to show molecular evidence (presence of | |||||||
| Tavares et al. ( |
| Previously identified using various physiological, biochemical and molecular techniques (Zhang et al. | Rhamnolipid | ESI-LTQ Orbitrap Hybrid MS | 780 | Orcinol assay with a conversion factor of 2.00 | NA |
| Additional information/remarks: Rha2-C10-C10 was identified as the prevalent congener with no species of C14-C14 reported. Also mono-fatty acid congeners such as Rha2-C8, C10 and C12 were also reported. Need molecular evidence to show the presence of | |||||||
| Dubeau et al. ( |
| Obtained from national collection | Rhamnolipid | HPLC/MS/MS, ESI-MS and NMR spectroscopy | Not specified | NA | Yes: gene structure and arrangement similar to that observed in |
| Additional information/remarks: Rha2-C14-C14 was considered to be the most prevalent rhamnolipid congener | |||||||
NA not available, TLC thin-layer chromatography, ESI-MS electrospray ionisation mass spectrometry, FTIR Fourier transform infrared spectrometry, NMR nuclear magnetic resonance, HPLC/MS high-performance liquid chromatography mass spectrometry